5KBR

Pak1 in complex with 7-azaindole inhibitor

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.36 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.198 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history. 


Literature

Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

McCoull, W., Hennessy, E.J., Blades, K., Chuaqui, C., Dowling, J.E., Ferguson, A.D., Goldberg, F.W., Howe, N., Jones, C.R., Kemmitt, P.D., Lamont, G., Varnes, J.G., Ward, R.A., Yang, B.

(2016) ACS Med Chem Lett 7: 1118-1123

  • DOI: https://doi.org/10.1021/acsmedchemlett.6b00322
  • Primary Citation of Related Structures:  
    5KBQ, 5KBR

  • PubMed Abstract: 

    • Group I p21-activated kinase (PAK) inhibitors are indicated as important in cancer progression, but achieving high kinase selectivity has been challenging. A bis-anilino pyrimidine PAK1 inhibitor was identified and optimized through structure-based drug design to improve PAK1 potency and achieve high kinase selectivity, giving in vitro probe compound AZ13705339 ( 18 ) ...

    Group I p21-activated kinase (PAK) inhibitors are indicated as important in cancer progression, but achieving high kinase selectivity has been challenging. A bis-anilino pyrimidine PAK1 inhibitor was identified and optimized through structure-based drug design to improve PAK1 potency and achieve high kinase selectivity, giving in vitro probe compound AZ13705339 ( 18 ). Reduction of lipophilicity to lower clearance afforded AZ13711265 ( 14 ) as an in vivo probe compound with oral exposure in mouse. Such probes will allow further investigation of PAK1 biology.

    Organizational Affiliation: 

    AstraZeneca , Gatehouse Park, Waltham, Massachusetts 02451, United States.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Serine/threonine-protein kinase PAK 1A, B289Homo sapiensMutation(s): 3 
Gene Names: PAK1
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q13153 (Homo sapiens)
Explore Q13153 
Go to UniProtKB:  Q13153
PHAROS:  Q13153
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ13153
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
IPW
Query on IPW
Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]		(4-chlorophenyl)-[5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridin-3-yl]methanone
C22 H20 Cl N5 O
AJHFOGJCDKOZKC-UHFFFAOYSA-N		 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
IPW Binding MOAD:  5KBR IC50: 260 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.36 Å
  • R-Value Free: 0.255 
  • R-Value Work: 0.195 
  • R-Value Observed: 0.198 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 61.818α = 90
b = 81.827β = 107.05
c = 65.914γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
SCALAdata scaling
Cootmodel building
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


View more in-depth experimental data
Entry History 

Deposition Data

  • Released Date: 2016-09-28 
    • Deposition Author(s): Ferguson, A.

Revision History  (Full details and data files)

  • Version 1.0: 2016-09-28
    Type: Initial release
  • Version 1.1: 2017-01-11
    Changes: Database references